Sarepta Therapeutics: Discretion Is the Better Part of Valor
Sarepta Therapeutics has been on an incredible bull run because of its experimental DMD therapy eteplirsen. Shareholders nevertheless need to consider taking one of two simple steps right now to protect themselves in case things reverse course in a hurry.
BioMarin's DMD Drug Faces Obstacles Tomorrow
An FDA advisory committee will consider the company's therapy for Duchenne muscular dystrophy and its conclusions could impact competitor Sarepta Therapeutics.